Validation of FACBC as an Early Indicator of Sub-clinical Metastatic Disease Among High-risk Prostate Cancer Patients With Presumed Localized Disease

Condition: Cancer

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT03081884

Sponsor: Emory University

Phase: Phase 2


  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • High-risk prostate cancer patients eligible for standard of care surgery
  • At least clinical T3a disease, and/or Gleason≥8, and/or Prostate-Specific Antigen (PSA) >20, as per clinical assessment and routine guidelines
  • Undergone standard of care conventional imaging (CT and/or MRI; bone scan and/or sodium fluoride (NaF) PET)

Exclusion Criteria:

  • Definitive findings of systemic metastasis on conventional imaging.

View trial on